Patents by Inventor Domenico Russo
Domenico Russo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230147302Abstract: The present invention relates to micronised pharmaceutical products of crystalline opicapone with a percentage number of sheaf agglomerates less than or equal to 30%. The invention also relates to methods of production of these micronised pharmaceutical products and their use in improving bioavailability of opicapone in the treatment of Parkinson's disease. Furthermore, the invention provides methods for calculating the primary particle size distribution and agglomerate content of such products.Type: ApplicationFiled: March 12, 2021Publication date: May 11, 2023Inventors: Teófilo Vasconcelos, Domenico Russo, Ana Rita Gonçalves Da Cruz Ramos Pires, Sonia Maria Correia Dias
-
Patent number: 11078163Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.Type: GrantFiled: July 16, 2019Date of Patent: August 3, 2021Assignee: BIAL-PORTELA & Cª, S.A.Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Patent number: 11046654Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: July 9, 2018Date of Patent: June 29, 2021Assignee: BIAL-PORTELA & CA, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20200140391Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.Type: ApplicationFiled: July 16, 2019Publication date: May 7, 2020Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Patent number: 10329268Abstract: The present invention provides a compound of formula N wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-?-hydroxylase.Type: GrantFiled: September 12, 2014Date of Patent: June 25, 2019Assignee: Bial-Portela & CA, S.A.Inventors: Domenico Russo, Jorge Wahnon, William Maton, Beat T. Weber, Paula Jeronimo, Luisa Sousa, Pedro Barrocas, Rita Pires, Ricardo Lima, Teofilo Vasconcelos
-
Publication number: 20190135764Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: July 9, 2018Publication date: May 9, 2019Inventors: Carla Patricia da Costa Pereira ROSA, Rita GUSMAO DE NORONHA, Laszlo Erno KISS, Patricio Manuel Vieira Araujo SOARES DA SILVA, Domenico RUSSO, Jorge Bruno Reis WAHNON, William MATON
-
Patent number: 10023541Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: December 19, 2016Date of Patent: July 17, 2018Assignee: BIAL-PORTELA & Ca, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Patent number: 9630955Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.Type: GrantFiled: July 31, 2015Date of Patent: April 25, 2017Inventors: Domenico Russo, Laszlo Erno Kiss, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Tibor Eszenyi, Axel Zimmermann, Bjoern Schlummer, Michael Kreis, Klaus Reiter
-
Publication number: 20170101381Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: December 19, 2016Publication date: April 13, 2017Inventors: Carla Patricia da Costa Pereira ROSA, Rita GUSMAO DE NORONHA, Laszlo Erno KISS, Patricio Manuel Vieira Araujo SOARES DA SILVA, Domenico RUSSO, Jorge Bruno Reis WAHNON, William MATON
-
Patent number: 9549915Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: July 24, 2013Date of Patent: January 24, 2017Assignee: BIAL-PORTELA & CA, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20170001962Abstract: The present invention concerns a process for preparing a compound having the Formula A: or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa?, with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa?, and wherein the compound substituents are as defined herein.Type: ApplicationFiled: January 23, 2015Publication date: January 5, 2017Applicant: BIAL-PORTELA & Cª, S.A.Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Publication number: 20160221981Abstract: The present invention provides a compound of formula N wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-?-hydroxylase.Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Inventors: Domenico RUSSO, Jorge WAHNON, William MATON, Beat T. WEBER, Paula JERÓNIMO, Luísa SOUSA, Pedro BARROCAS, Rita PIRES, Ricardo LIMA, Teófilo VASCONCELOS
-
Publication number: 20160009700Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.Type: ApplicationFiled: July 31, 2015Publication date: January 14, 2016Inventors: Domenico Russo, Laszlo Erno Kiss, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Tibor Eszenyi, Axel Zimmermann, Bjoern Schlummer, Michael Kreis, Klaus Reiter
-
Patent number: 9126988Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.Type: GrantFiled: December 12, 2012Date of Patent: September 8, 2015Assignee: BIAL—PORTELA & CA, S.A.Inventors: Domenico Russo, Laszlo Erno Kiss, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Tibor Eszenyi, Axel Zimmermann, Bjoern Schlummer, Michael Kreis, Klaus Reiter
-
Publication number: 20150197503Abstract: A process for preparing a substituted urea compound of Formula II or Formula I, or a pharmaceutically acceptable salt or ester thereof, Formula II, Formula I the process comprising the reaction of an intermediate of Formula II? or Formula 1?, Formula II?, Formula I? with a carbamoyl halide of the formula: R1R2NC(=0)Hal, in a solvent consisting essentially of pyridine, wherein Hal represents Cl, F, I or Br, and wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.Type: ApplicationFiled: July 26, 2013Publication date: July 16, 2015Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Publication number: 20150174103Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: July 24, 2013Publication date: June 25, 2015Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Patent number: 8908194Abstract: A measuring machine includes a mobile unit to move a measurement sensor in a measurement volume. The mobile unit includes at least one member mobile along an axis under the thrust of driving means and being subjected to dynamic deformations. A laser sensor is provided with a laser emitter fixed to a first portion of the mobile member and a target fixed to a second portion of the mobile member and designed to receive a laser beam generated by the emitter. Means are provided for compensating for measurement errors of the machine resulting from the dynamic deformations of the mobile unit and in response to displacement of a point of incidence of the laser beam on the target with respect to a reference position in undeformed conditions, the displacement of the point resulting from the relative displacement of the first and second portions of the mobile member.Type: GrantFiled: December 27, 2007Date of Patent: December 9, 2014Assignee: Hexagon Metrology S.p.A.Inventors: Michele Verdi, Giampiero Guasco, Domenico Russo
-
Publication number: 20140350057Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.Type: ApplicationFiled: December 12, 2012Publication date: November 27, 2014Applicant: BIAL - PORTELA & CA, S.A.Inventors: Domenico Russo, Laszlo Erno Kiss, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Tibor Eszenyi, Axel Zimmermann, Bjoern Schlummer, Michael Kreis, Klaus Reiter
-
Publication number: 20130232805Abstract: A measuring machine comprising a member mobile along an axis, an optical scale extending parallel to the axis, a first reading head, which is carried by the mobile member and co-operates with the optical scale, an additional sensor carried by the mobile member, and a processing unit co-operating with the first reading head and with the additional sensor for detecting data correlated with the state of thermal expansion of the optical scale.Type: ApplicationFiled: March 6, 2013Publication date: September 12, 2013Applicant: HEXAGON METROLOGY S.P.A.Inventor: Domenico RUSSO
-
Patent number: D714168Type: GrantFiled: November 27, 2013Date of Patent: September 30, 2014Assignee: Hexagon Metrology S.p.A.Inventors: Michele Verdi, Domenico Russo